argenex (ARGX) Competitors

Gilead Sciences has higher revenue and earnings than argenex. Gilead Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Gilead Sciences presently has a consensus target price of $159.33, indicating a potential upside of 3.77%. argenex has a consensus target price of $1,151.95, indicating a potential upside of 40.77%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Gilead Sciences.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Gilead Sciences had 2 more articles in the media than argenex. MarketBeat recorded 37 mentions for Gilead Sciences and 35 mentions for argenex. Gilead Sciences' average media sentiment score of 0.47 beat argenex's score of 0.09 indicating that Gilead Sciences is being referred to more favorably in the media.

Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, argenex has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Gilead Sciences' net margin of -10.64%. argenex's return on equity of 43.59% beat Gilead Sciences' return on equity.

Vertex Pharmaceuticals presently has a consensus target price of $579.81, suggesting a potential upside of 16.31%. argenex has a consensus target price of $1,151.95, suggesting a potential upside of 40.77%. Given argenex's higher probable upside, analysts plainly believe argenex is more favorable than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a net margin of 35.00% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat Vertex Pharmaceuticals' return on equity.

Vertex Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, argenex has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

In the previous week, argenex had 24 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 35 mentions for argenex and 11 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.84 beat argenex's score of 0.09 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has higher revenue and earnings than argenex. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

75.3% of Moderna shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

argenex has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Moderna presently has a consensus target price of $100.60, suggesting a potential downside of 55.55%. argenex has a consensus target price of $1,151.95, suggesting a potential upside of 40.77%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than Moderna.

argenex has a net margin of 32.19% compared to Moderna's net margin of -141.43%. argenex's return on equity of 43.59% beat Moderna's return on equity.

In the previous week, Moderna had 18 more articles in the media than argenex. MarketBeat recorded 53 mentions for Moderna and 35 mentions for argenex. Moderna's average media sentiment score of 0.29 beat argenex's score of 0.09 indicating that Moderna is being referred to more favorably in the media.

Moderna has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, argenex has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

argenex currently has a consensus price target of $1,151.95, suggesting a potential upside of 40.77%. Regeneron Pharmaceuticals has a consensus price target of $834.24, suggesting a potential upside of 7.18%. Given argenex's stronger consensus rating and higher probable upside, equities analysts clearly believe argenex is more favorable than Regeneron Pharmaceuticals.

argenex has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

In the previous week, argenex had 19 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 35 mentions for argenex and 16 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.00 beat argenex's score of 0.09 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Regeneron Pharmaceuticals has higher revenue and earnings than argenex. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

60.3% of argenex shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

argenex has a net margin of 32.19% compared to Regeneron Pharmaceuticals' net margin of 27.86%. argenex's return on equity of 43.59% beat Regeneron Pharmaceuticals' return on equity.